XNW3009
/ Evopoint
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
May 09, 2022
To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: The Affiliated Hospital of Qingdao University | Trial primary completion date: Apr 2022 ➔ Aug 2022
Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology
April 12, 2022
To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: The Affiliated Hospital of Qingdao University
New P1 trial • Gout • Inflammatory Arthritis • Rheumatology
January 06, 2022
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
(clinicaltrials.gov)
- P1; N=40; Completed; Sponsor: Sinovent Pty Ltd.; Recruiting ➔ Completed; N=72 ➔ 40
Clinical • Enrollment change • Trial completion • Gout • Inflammatory Arthritis • Rheumatology
March 09, 2021
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: Sinovent Pty Ltd.; Trial completion date: Oct 2020 ➔ May 2021; Trial primary completion date: Aug 2020 ➔ Jan 2021
Clinical • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology
December 06, 2019
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: Sinovent Pty Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
August 05, 2019
Newly added product
(clinicaltrials.gov)
- P1, Inflammation
Pipeline update
August 01, 2019
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
(clinicaltrials.gov)
- P1; N=72; Not yet recruiting; Sponsor: Sinovent Pty Ltd.
Clinical • New P1 trial
1 to 7
Of
7
Go to page
1